ABX464-908
13 evidence topics · 3 sources
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-908” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/10/2023” |
| End of trial | “End of trial 11/09/2024” |
Study design
Phase 1 multiple-dose design with matched controls
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Patients” |
| Age range | “Age range 65+ years, 18-64 years” |
Treatment
Multiple oral doses of obefazimod
Study outcomes
Rationale for using Obefazimod pharmacokinetics in hepatic impairment as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-908 has only an EU register record and a sentence in the Form 20-F. The register gives the title, the dates (9 October 2023 to 11 September 2024), one site in Germany, and 32 planned participants; the 20-F reports 30 enrolled participants with mild or moderate hepatic impairment or matched normal liver function. The 20-F states that the trial was completed in 2025, whereas the register gives 11 September 2024 as its end. The classification method for hepatic impairment, the dose, the number per group, and the endpoints are not public, severe hepatic impairment was not studied, and the summary of results is deferred until 11 March 2027. The 20-F describes the results only as “supportive data” for the NDA, so no exposure ratio or safety result is available to inform dosing in hepatic impairment.